RxDoctor Payments DataLook up a doctor →

Misti Hedgepeth, NP

Nurse Practitioner · McComb, MSNPI 1649753039

Payments from drug & device makers

$11,824in general payments, 2019–2025

Across 445 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharmacosmos Therapeutics Inc.$3K
  • Merck$675
  • Pfizer$569
  • AstraZeneca$559
  • Johnson & Johnson$546
  • Bristol Myers Squibb$396
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$1,76415%
  • Travel & lodging$7847%
  • Food & beverage$8,91975%
  • Education$3573%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pharmacosmos Therapeutics Inc.25$3,091
Merck26$675
Pfizer34$569
AstraZeneca27$559
Johnson & Johnson(2 entities)31$546
Bristol Myers Squibb23$396
Gilead(2 entities)11$291
Incyte Corporation15$288
Beigene USA, Inc.8$282
GSK14$274
Novartis16$270
Astellas Pharma US Inc10$261
E.r. Squibb & Sons, L.L.C.18$237
Daiichi Sankyo Inc.9$207
Boehringer Ingelheim5$187
Adaptive Biotechnologies Corporation7$185
EMD Serono, Inc.5$178
Bayer10$178
Genentech USA, Inc.8$175
Eisai Inc.10$167
Takeda Pharmaceuticals U.S.A., Inc.7$166
AVEO Pharmaceuticals, Inc.5$164
Array Biopharma Inc8$164
Exelixis Inc.8$145
Regeneron Healthcare Solutions, Inc.7$141
Sanofi7$126
Ipsen Biopharmaceuticals, Inc5$113
Itamar Medical Inc1$102
Jazz Pharmaceuticals Inc.5$101
Genmab U.S., Inc.5$98
Sanofi-aventis U.S. LLC1$95
Stemline Therapeutics Inc.4$94
Pharmaessentia USA Corporation4$92
AbbVie5$87
Lilly USA, LLC4$82
Puma Biotechnology, Inc.5$82
Seagen Inc.5$72
Beone Medicines USA, Inc.3$53
Sobi, Inc2$50
Mirati Therapeutics, Inc.3$50
ADC Therapeutics America, Inc.3$49
Abbott3$48
Geron Corporation2$44
Dendreon Pharmaceuticals LLC2$44
Taiho Oncology, Inc.2$42
Rigel Pharmaceuticals, Inc.2$42
Morphosys, US Inc.2$40
Karyopharm Therapeutics Inc.2$39
Coherus Oncology, Inc.2$37
Alnylam Pharmaceuticals Inc.2$36
Blueprint Medicines Corporation1$33
Spectrum Pharmaceuticals Inc.2$32
Shield Therapeutics Inc2$31
Progenics Pharmaceuticals, Inc.1$31
Servier Pharmaceuticals LLC1$23
Pharmacyclics LLC, An Abbvie Company1$23
Siemens Medical Solutions USA, Inc.1$23
Azurity Pharmaceuticals, Inc.1$20
Celltrion USA Inc.1$19
Fresenius Kabi USA, LLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,824 in reported general payments places this provider in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$75,497
Medicare patients
431
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide85$1,144,560
RevlimidLenalidomide46$816,245
LenvimaLenvatinib Mesylate32$759,842
PomalystPomalidomide27$494,982
NubeqaDarolutamide26$340,202
BrukinsaZanubrutinib19$245,877
VenclextaVenetoclax35$236,197
AlecensaAlectinib Hcl12$161,928
Abiraterone Acetate30$119,348
EliquisApixaban113$73,350
XareltoRivaroxaban26$15,093
Anastrozole343$3,821
Imatinib Mesylate14$2,474
Potassium Chloride123$1,709
Oxycodone Hcl102$1,636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$261$1,144,56085 claims
Bristol Myers SquibbRevlimid$396$816,24546 claims
Eisai Inc.Lenvima$167$759,84232 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$237$494,98227 claims
BayerNubeqa$178$340,20226 claims
Beigene USA, Inc.Brukinsa$282$245,87719 claims
AbbVieVenclexta$87$236,19735 claims
Genentech USA, Inc.Alecensa$175$161,92812 claims
PfizerEliquis$569$73,350113 claims
Johnson & JohnsonXarelto$546$15,09326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in McComb

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →